Search results
Results from the WOW.Com Content Network
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset , myoclonic , or tonic–clonic seizures, [ 7 ] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein .
Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. [5] [6] It has been approved since 2016.
The action of drugs on the human body (or any other organism's body) is called pharmacodynamics, and the body's response to drugs is called pharmacokinetics. The drugs that enter an individual tend to stimulate certain receptors, ion channels, act on enzymes or transport proteins. As a result, they cause the human body to react in a specific way.
750 mg KEPPRA tablets are orange, oblong-shaped, scored, film-coated tablets marked with “ucb 750” on one side. 1000 mg KEPPRA tablets are white, oblong-shaped, scored, film-coated tablets marked with “ucb 1000” on one side. KEPPRA oral solution is a clear, colorless, grape-flavored liquid.
In pharmacology, the term mechanism of action (MOA) refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. [2] A mechanism of action usually includes mention of the specific molecular targets to which the drug binds, such as an enzyme or receptor . [ 3 ]
Seletracetam (UCB 44212) is a pyrrolidone-derived [2] drug of the racetam family that is structurally related to levetiracetam (trade name Keppra). [ 2 ] [ 3 ] It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.
Explore the concept of PK/PD models, which integrate pharmacokinetics and pharmacodynamics to optimize drug dosing and efficacy.
Safety pharmacology is a branch of pharmacology specialising in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above. [1] Primary organ systems (so-called core battery systems) are: Central Nervous System